C-Peptide Sex- and Cycle-Related Differences: Normal Range, Optimal Levels, and What Your Result Means

What C-Peptide Actually Measures

C-peptide is a 31-amino-acid chain removed from proinsulin when the pancreas cleaves the molecule into active insulin plus this connecting peptide. Because the pancreas secretes both in a 1:1 molar ratio, and because C-peptide is not extracted by the liver on first pass, serum C-peptide gives a more stable and complete picture of beta-cell secretion than insulin itself 1.

Why C-Peptide Outperforms Insulin for Certain Questions

Insulin undergoes roughly 50% first-pass hepatic extraction, meaning peripheral insulin levels underestimate total pancreatic output. C-peptide bypasses that extraction almost entirely 2. The clinical payoff is straightforward: a person injecting exogenous insulin will have suppressed or undetectable C-peptide because exogenous insulin suppresses the beta cell, yet their peripheral insulin is elevated. That pattern identifies factitious hypoglycemia or confirms true type 1 diabetes with beta-cell failure.

Fasting vs. Stimulated Measurements

Fasting C-peptide captures basal secretion. A stimulated value, drawn 90 to 120 minutes after a mixed meal or 6 minutes after a 1 mg glucagon IV challenge, captures maximal reserve. The American Diabetes Association notes that a stimulated C-peptide above 0.2 nmol/L (roughly 0.6 ng/mL) is the threshold used in the T1D Exchange and TrialNet protocols to define residual beta-cell function 3. Healthy adults generally produce 5 to 12 ng/mL at 2 hours post-meal, a range that narrows sharply with progressive beta-cell loss.

Normal Range and Optimal Targets

Population Reference Range

Commercial laboratories report a fasting reference interval of approximately 0.5 to 2.0 ng/mL (SI: 0.17 to 0.66 nmol/L) in non-diabetic adults 4. That interval is wide because it encompasses a heterogeneous population spanning lean young women, insulin-resistant older men, and everyone between. The reference range tells you whether a result is statistically unusual. It does not tell you whether a result is metabolically healthy.

The Longevity-Medicine Optimal Window

Functional and longevity-medicine practitioners commonly target a tighter fasting window of 0.8 to 1.8 ng/mL for adults without diabetes who are optimizing metabolic health. The reasoning: values persistently above 2.0 ng/mL in a fasting, non-diabetic individual suggest compensatory hyperinsulinemia, a state linked to increased cardiovascular risk in the San Antonio Heart Study (N=2,569), where the top quartile of fasting insulin (a proxy for C-peptide) carried a hazard ratio of 1.63 for incident coronary disease over 8 years 5. Values below 0.5 ng/mL in a person eating a carbohydrate-containing diet raise suspicion for beta-cell insufficiency.

Conversion Between Units

Many European labs report C-peptide in nmol/L. Multiply ng/mL by 0.331 to convert to nmol/L. A fasting value of 1.5 ng/mL equals 0.50 nmol/L. Misreading units is the most common source of clinical confusion in practice.

Sex Differences in Baseline C-Peptide

Men vs. Women: What the Data Show

Men tend to have modestly higher fasting C-peptide than age-matched premenopausal women when expressed per kilogram of lean mass, though absolute values are often similar or slightly higher in women due to higher percent body fat increasing insulin demand. A cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES 2003 to 2010, N=5,587 non-diabetic adults) found that after adjusting for BMI and age, male sex was independently associated with higher fasting C-peptide by approximately 0.12 ng/mL 6. The difference, while statistically significant (P<0.001), is small relative to within-individual variation across meal timing and body composition.

Why Sex Hormones Drive This Gap

Estrogen at physiologic concentrations enhances hepatic insulin clearance and peripheral insulin sensitivity through estrogen receptor-alpha signaling in skeletal muscle 7. Greater insulin sensitivity means the beta cell needs to secrete less C-peptide to maintain euglycemia. Testosterone, by contrast, promotes visceral adiposity at supraphysiologic doses and modestly reduces whole-body insulin sensitivity at the doses used in testosterone replacement therapy (TRT), though this effect is dose-dependent and partly offset by testosterone's direct anabolic effects on muscle mass 8.

Menstrual Cycle Phase and C-Peptide Fluctuation

Follicular Phase Baseline

During the early follicular phase, estradiol is low (typically 30 to 120 pg/mL) and progesterone is near zero. Insulin sensitivity is at or near its cycle peak in this window. A controlled metabolic study by Ter Horst et al. (N=22 healthy women) found whole-body insulin sensitivity measured by hyperinsulinemic-euglycemic clamp to be 12% higher in the follicular phase than the mid-luteal phase 9. Higher insulin sensitivity means the beta cell secretes less C-peptide per unit of glucose challenge.

Luteal Phase Shift

Progesterone rises to 5 to 20 ng/mL in the mid-luteal phase and attenuates insulin receptor signaling at a post-receptor step. The result is a measurable increase in fasting and postprandial C-peptide. In Ter Horst et al., fasting C-peptide was approximately 14% higher in the mid-luteal compared to the early follicular phase 9. A separate study of 17 premenopausal women by Yeung et al. Confirmed that insulin secretion, estimated by C-peptide area under the curve during an oral glucose tolerance test, was higher in the luteal phase, driven primarily by progesterone-mediated insulin resistance 10.

Clinical Implication: When to Draw the Test

For the most reproducible result in premenopausal women, draw fasting C-peptide on days 2 to 7 of the menstrual cycle (early follicular). Luteal-phase draws may overestimate basal secretory capacity by 10 to 15%. Document cycle day on the lab requisition whenever possible.

Hormonal Contraceptives and C-Peptide

Combined Oral Contraceptives

Combined oral contraceptives (COCs) containing ethinyl estradiol plus a progestin increase hepatic sex hormone-binding globulin production and alter insulin sensitivity in a progestin-type-dependent manner. Levonorgestrel-containing COCs show the most pronounced insulin resistance; newer progestins like drospirenone show a more neutral or even mildly favorable metabolic profile 11. A meta-analysis of 42 studies by Petitti et al. Found that COC users had statistically higher fasting insulin and C-peptide compared to non-users, with levonorgestrel formulations producing the largest effect 12.

Progestin-Only and IUD Methods

Progestin-only methods, including the levonorgestrel intrauterine device (IUD) and depot medroxyprogesterone acetate (DMPA), produce variable effects. DMPA has the strongest evidence for increasing fasting C-peptide, with one 12-month prospective study (N=93) showing a 19% increase in fasting C-peptide over baseline at month 12 13. The levonorgestrel IUD delivers lower systemic exposure and shows minimal measurable change in fasting C-peptide in most studies.

Estrogen Therapy: Oral vs. Transdermal Routes

Oral Estrogen Increases C-Peptide More Than Transdermal

Oral estrogen, absorbed via the portal circulation, reaches the liver at concentrations 4 to 5 times higher than systemic levels and suppresses hepatic insulin clearance. The result is higher circulating insulin and, through beta-cell feedback via lower portal glucose, a secondary increase in C-peptide secretion. A randomized crossover trial by Godsland et al. Compared oral 17-beta-estradiol (2 mg/day) to transdermal estradiol (50 mcg/day patch) in 40 postmenopausal women over 12 weeks each. Oral estradiol increased fasting C-peptide by a mean of 22% above baseline; transdermal estradiol increased it by only 6%, a difference the authors attributed entirely to differential hepatic first-pass effects 14.

Why This Matters for HRT Prescribing

Postmenopausal women already at elevated cardiometabolic risk, particularly those with fasting C-peptide above 1.8 ng/mL at baseline, may benefit from transdermal rather than oral estradiol to avoid further amplifying hyperinsulinemia. The Endocrine Society's 2015 postmenopausal hormone therapy guideline notes that route of administration is a clinically relevant variable for metabolic risk stratification 15.

Testosterone Replacement Therapy and C-Peptide

Physiologic TRT in Hypogonadal Men

In men with documented hypogonadism (total testosterone <300 ng/dL), testosterone replacement at standard doses (typically testosterone cypionate 100 to 200 mg IM every 1 to 2 weeks, or equivalent) tends to reduce fasting C-peptide by improving insulin sensitivity as lean mass increases and visceral fat decreases. A 12-month randomized trial by Kapoor et al. (N=24 hypogonadal men with type 2 diabetes) showed a 0.35 ng/mL reduction in fasting C-peptide alongside improved HbA1c after testosterone undecanoate therapy 16.

Supraphysiologic Doses and Anabolic Steroids

Supraphysiologic testosterone or anabolic androgenic steroids (AAS) at doses used in bodybuilding (300 to 600 mg/week testosterone equivalents) show a different pattern. Visceral adiposity may increase with certain AAS, and aromatization to estradiol at high doses adds an estrogenic component. One cross-sectional study of 34 AAS users found fasting C-peptide 28% above matched non-users, with HOMA-IR elevated proportionally 17. This elevation likely reflects increased beta-cell demand from AAS-associated insulin resistance rather than true beta-cell pathology.

Female TRT: Low-Dose Testosterone in Women

Women prescribed low-dose testosterone (typically 0.5 to 2 mg/day topical), increasingly common in perimenopause protocols, have minimal data on C-peptide changes at physiologic female replacement doses. The available evidence does not support a clinically meaningful change in fasting C-peptide at testosterone levels kept within the female reference range (15 to 70 ng/dL) 18.

GLP-1 Receptor Agonists and C-Peptide Interpretation

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) directly stimulate beta-cell insulin secretion in a glucose-dependent manner. Patients on these agents will have higher stimulated C-peptide values during a glucose challenge than drug-naive individuals, though fasting C-peptide changes are more modest. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks vs. 2.4% placebo 19. The accompanying weight loss and improved insulin sensitivity typically reduce fasting C-peptide toward the optimal 0.8 to 1.8 ng/mL window over 16 to 24 weeks in insulin-resistant patients. Clinicians should not interpret a falling C-peptide on GLP-1 therapy as beta-cell loss; it reflects improved insulin sensitivity reducing secretory demand.

Renal Function and C-Peptide Interpretation

C-peptide is filtered and degraded by the kidney. When eGFR falls below 45 mL/min/1.73m², C-peptide accumulates and fasting values may exceed 2.0 ng/mL even in patients with normal beta-cell function or type 2 diabetes on insulin 20. The American Diabetes Association guideline on C-peptide testing explicitly flags renal impairment as a required co-variate when interpreting results 3. Always obtain a same-day or recent eGFR when C-peptide is drawn.

How to Collect a Reproducible C-Peptide Sample

Pre-Draw Standardization

The single largest source of within-individual variability is meal timing. C-peptide peaks 60 to 90 minutes after carbohydrate ingestion and may remain above fasting baseline for 3 to 4 hours. A true fasting sample requires at minimum 8 hours of no caloric intake, with 10 to 12 hours preferred for optimal suppression. Water and medications without caloric content are acceptable.

Specimen Handling

C-peptide is stable in serum at room temperature for up to 24 hours and can be frozen at minus 20°C for months without significant degradation, which gives it a practical handling advantage over insulin 21. EDTA plasma is acceptable at most labs; confirm with the processing laboratory before collection.

Timing Relative to Hormone Therapies

• Women on COCs: draw during the pill-free or placebo week for the most hormone-naive result.
• Postmenopausal women on oral estradiol: note dose and duration on the requisition; consider transdermal conversion before retesting if C-peptide is above 2.0 ng/mL without other explanation.
• Men on TRT: draw at trough (before the next injection or gel application) for a consistent snapshot across serial tests.
• Women on progesterone supplementation (luteal support or HRT): note the progesterone dose; expect values 10 to 20% above the patient's follicular-phase baseline.

Interpreting Results in Context: A Practical Decision Tree

| Fasting C-Peptide | Most Likely Interpretation | Recommended Next Step | |---|---|---| | <0.2 ng/mL | Severe beta-cell failure (T1D or late T2D) | Anti-GAD, anti-IA2 antibodies; endocrinology referral | | 0.2 to 0.5 ng/mL | Borderline low; possible early T1D or T2D with significant loss | Glucagon stimulation test; antibody panel | | 0.5 to 0.8 ng/mL | Low-normal; watch for progression with annual retest | Optimize insulin sensitivity; annual monitoring | | 0.8 to 1.8 ng/mL | Optimal metabolic range (longevity target) | Maintain; recheck in 12 months | | 1.8 to 3.0 ng/mL | Compensatory hyperinsulinemia likely | Assess HOMA-IR, fasting glucose, insulin, BMI | | >3.0 ng/mL | High; rule out insulinoma, severe IR, CKD | Imaging, eGFR, 72-hr fast if hypoglycemia present |

Direct Quotations from Guideline Documents

The American Diabetes Association Standards of Medical Care in Diabetes 2022 state: "C-peptide measurement can help distinguish type 1 from type 2 diabetes when the diagnosis is unclear, with a stimulated C-peptide <0.2 nmol/L indicating marked insulin deficiency." 3

The Endocrine Society's Clinical Practice Guideline on Testosterone Therapy in Men states: "In men with testosterone deficiency, testosterone therapy improves body composition, reduces fat mass, and may improve insulin sensitivity." 22